Effectiveness and Safety of Insulin Glulisine When Initiating Supplementary Prandial Insulin Treatment (SIT) in Insulin-Naïve Patients with Type 2 Diabetes: The Observational IGLU-SIT Study
Open Access
- 5 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetes Therapy
- Vol. 12 (3), 733-747
- https://doi.org/10.1007/s13300-021-00998-z
Abstract
Introduction The IGLU-SIT study documented the effectiveness of initiating supplementary prandial insulin treatment (SIT) with insulin glulisine after failure of oral antidiabetic drugs alone in patients with type 2 diabetes (T2DM) in a real-world setting in Germany. Methods The IGLU-SIT study was an open-label, prospective, multicentre, non-interventional study with an observation period of 12 ± 1 months. The primary objective was to determine the proportion of patients reaching their pre-defined glycosylated haemoglobin (HbA1c) goal at 3, 6, 9 and 12 months. Selected secondary objectives were absolute change in HbA1c, a 7-point blood glucose profile, and rate of hypoglycaemia. Data were evaluated overall and by age group (< 65, 65–74 and ≥ 75 years). Results Overall, 215 patients with T2DM were observed in 64 centres. Baseline HbA1c was 8.3%, and mean HbA1c target was 6.8% (baseline 8.1% and target 6.9% in patients ≥ 75 years). Individual HbA1c target attainment in patients peaked at 38.9% (95% confidence interval [CI] 32.1–46.1%) after 12 months; this was 45.9% in patients aged ≥ 75 years. The mean HbA1c reduction was 1.12 ± 1.05% (p < 0.0001) with only minor differences by age group. A 7-point blood glucose profile revealed significant reductions (p < 0.0001) at all time-points. The rate of confirmed symptomatic hypoglycaemia was 2.2% (95% CI 0.7–5.1) during the 12-month follow-up; rates were increased in patients aged ≥ 75 years (7.0%; 95% CI 1.5–19.1) as were the rates of adverse events (17.8 vs. 6.1%). Conclusion Initiating SIT with insulin glulisine is an appropriate treatment option in patients whose T2DM is insufficiently controlled. Particular attention should be paid to elderly patients in whom higher attainment rates of treatment target were associated with adverse events. Trial Registration https://awbdb.bfarm.de; Identifier: 6819; Date of registration: 23.06.2016Funding Information
- Sanofi-Aventis Deutschland GmbH
This publication has 16 references indexed in Scilit:
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDEuropean Heart Journal, 2013
- Substantial Increase in Incidence of Severe Hypoglycemia Between 1997–2000 and 2007–2010Diabetes Care, 2012
- Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemiaCardiovascular Diabetology, 2012
- Comparable Efficacy and Safety of Insulin Glulisine and Insulin Lispro When Given as Part of a Basal–Bolus Insulin Regimen in a 26-Week Trial in Pediatric Patients with Type 1 DiabetesDiabetes Technology & Therapeutics, 2011
- Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetesDiabetes, Obesity and Metabolism, 2011
- Insulin Glulisine Has a Faster Onset of Action Compared with Insulin Aspart in Healthy VolunteersExperimental and Clinical Endocrinology & Diabetes, 2010
- The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD studyBMJ, 2010
- Effects of insulin glulisine as mono‐ or add‐on therapy in patients with type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2009
- Benefits of Complementary Therapy with Insulin Aspart Versus Human Regular Insulin in Persons with Type 2 Diabetes MellitusDiabetes Technology & Therapeutics, 2007
- The Switch from Sulfonylurea to Preprandial Short- Acting Insulin Analog Substitution Has an Immediate and Comprehensiveβ-Cell Protective Effect in Patients with Type 2 Diabetes MellitusDiabetes Technology & Therapeutics, 2006